# Phase 1 recurrence trials recruiting: 147 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 147 trials in phase 1 for recurrence that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 recurrence trials: 147 rows for $7.35, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 147
- Recruiting or not yet: 147
- Read on: November 19, 2026

## Trials

The 25 newest of 147, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947043 | Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection | Tongji Hospital | Phase 1 | Recruiting | Recurrent or Metastatic Lung Cancer or Cervical Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947043) |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 10, 2026 | NCT07929909 | A Phase I Clinical Study of YN003 in the Treatment of Glioma | Beijing Inno Medicine Co., Ltd. | Phase 1 | Recruiting | Glioma, Glioblastoma, Brain Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929909) |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| November 10, 2026 | NCT07927842 | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927842) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| October 27, 2026 | NCT07897136 | CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897136) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 8, 2026 | NCT07865130 | Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Medulloblastoma Recurrent, Medulloblastoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865130) |
| September 25, 2026 | NCT07842445 | Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. | Great Novel Therapeutics Biotech & Medicals Corporation | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842445) |
| September 25, 2026 | NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841002) |
| August 21, 2026 | NCT07779798 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With... | Crossbow Therapeutics, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779798) |
| August 19, 2026 | NCT07773454 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors | Exelixis | Phase 1 | Not yet recruiting | Cancer, Pediatric Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773454) |
| August 14, 2026 | NCT07765966 | Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias | RiboX Therapeutics Ltd. | Phase 1 | Not yet recruiting | Immune Thrombocytopenia (ITP) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765966) |
| August 13, 2026 | NCT07763938 | CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | The First Affiliated Hospital with Nanjing Medical University | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Malignancies | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763938) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 20, 2026 | NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715630) |
| July 20, 2026 | NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Treeline Biosciences, Inc. | Phase 1 | Recruiting | Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713732) |
| July 7, 2026 | NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Renal Cell Carcinoma, Advanced, Recurrent, Refractory | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686744) |
| June 25, 2026 | NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | iCell Gene Therapeutics | Phase 1 | Recruiting | Acute Myeloid Leukemia (AML) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668557) |
| June 5, 2026 | NCT07628582 | A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies | The First Affiliated Hospital with Nanjing Medical University | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Malignancies | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628582) |
| May 14, 2026 | NCT07586618 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic... | Allterum Therapeutics, Inc | Phase 1 | Recruiting | Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586618) |
| May 13, 2026 | NCT07585071 | IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Autoimmune Hemolytic Anemia, Relapsed/Refractory | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585071) |
| May 13, 2026 | NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Sun Yat-sen University | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584499) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 5 |
| UNC Lineberger Comprehensive Cancer Center | 5 |
| The First Affiliated Hospital of Soochow University | 4 |
| The First Affiliated Hospital with Nanjing Medical University | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 |
| Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | 2 |
| University of Colorado, Denver | 2 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| Treeline Biosciences, Inc. | 2 |
| Beijing GoBroad Hospital | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| Baylor College of Medicine | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Excyte Biopharma Ltd | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Hangzhou Weben Pharma Co., Ltd | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| MSD R&D (China) Co., Ltd. | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| IDEAYA Biosciences | 1 |
| Nanjing IASO Biotechnology Co., Ltd. | 1 |
| Lantern Pharma Inc. | 1 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 1 |
| Dana-Farber Cancer Institute | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 68 |
| China | 57 |
| Spain | 10 |
| France | 8 |
| South Korea | 8 |
| Australia | 8 |
| Japan | 5 |
| United Kingdom | 5 |
| Poland | 5 |
| Netherlands | 4 |
| Canada | 4 |
| Italy | 3 |
| Austria | 2 |
| Denmark | 2 |
| Taiwan | 2 |
| Israel | 2 |
| Belgium | 1 |
| Germany | 1 |
| Brazil | 1 |
| Bulgaria | 1 |
| Russia | 1 |
| Iran | 1 |
| Switzerland | 1 |
| Georgia | 1 |
| Greece | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Jewelry manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-manufacturers/united-states)
- [B2B transportation and storage companies in the United States](https://specstream.ai/data/businesses/b2b-transportation-and-storage-companies/united-states)
- [Packing services in the United States](https://specstream.ai/data/businesses/packing-services/united-states)
- [Construction companies in the United States](https://specstream.ai/data/businesses/construction-companies/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
